Rational Design of Vaccines Against Hepatitis C Virus (U19 Clinical Trial Not Allowed)
What this funding is for: To create a consortium of Research Centers that design, optimize, evaluate, and advance broadly protective hepatitis C virus (HCV) vaccines, including completing IND-enabling studies to move the best candidates into clinical testing.
Why it matters: HCV causes chronic infection in most cases and leads to serious liver disease. Despite effectiv…
The purpose of this notice of funding opportunity (NOFO) is to establish a consortium of Research Centers that focus on the design, optimization, evaluation, and development of broadly protective vaccines for hepatitis C virus (HCV) and the performance of investigational new drug (IND)-enabling …
Source
Tags
Similar opportunities
-
Rational Design of Vaccines Against Hepatitis C Virus (U19 Clinical Trial Not Allowed)
-
Pilot Projects to Enhance the Human Virome Program (R03, Clinical Trials Not Allowed)
-
Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed)
-
Development of Novel or Improved Infertility Technologies (R61/R33 Clinical Trial Optional)
-
Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed)